Applying Iterative Machine Learning to Expand GPCR Therapeutics Beyond GLP-1

• Demonstrating how internally generated biological data can continuously improve GPCR prediction performance across successive discovery campaigns
• Transferring learnings from GLP-1-focused programs to accelerate discovery against novel intestinal GPCR targets
• Advancing next-generation peptide therapeutics for muscle preservation, metabolic health and post-GLP-1 patient support through AI-enabled discovery

Speakers:

Zohar Barbash

Chief Technology Officer & Co-Founder

LEMBAS